{"schema_version":"secwatch.filing_event.v1","accession":"0001802768-23-000027","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.530231+00:00","generated_at":"2026-06-08T10:12:23.511872+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Royalty Pharma Q3 2023: $637M Adj Cash Receipts (+7% YoY); raises FY23 guidance","bullets":["Adjusted Cash Receipts of $637M (+7% YoY); operating cash flow $574M (+6%).","Raised FY 2023 guidance for Adjusted Cash Receipts to $2,950M-$3,000M (prev. $2,900M-$2,975M).","Year-to-date announced transactions of up to $3.8B, including $2.1B in upfront payments.","CF franchise royalties $238M (+14%); Trelegy $58M (+36%); Evrysdi $16M (+64%)."],"urls":{"canonical":"https://secwatch.observer/filing/0001802768-23-000027","json":"https://secwatch.observer/filing/0001802768-23-000027.json","markdown":"https://secwatch.observer/filing/0001802768-23-000027.md","text":"https://secwatch.observer/filing/0001802768-23-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000180276823000027/0001802768-23-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000180276823000027/rprx-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T10:12:23.511872+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6d40a42f92e9ddacaced263e190272c7e02eda0b","claim":"Royalty Pharma plc updated its the quarter ended September 30, 2023 guidance (raised).","evidence_excerpt":"On November 8, 2023, Royalty Pharma plc issued a press release announcing its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276823000027/0001802768-23-000027-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}